Meag Munich Ergo Kapitalanlagegesellschaft Mbh Has Lowered Its 3M Co (MMM) Stake; Epizyme Has 1.28 Sentiment

3M Company (NYSE:MMM) Logo

Meag Munich Ergo Kapitalanlagegesellschaft Mbh decreased 3M Co (MMM) stake by 89.29% reported in 2018Q3 SEC filing. Meag Munich Ergo Kapitalanlagegesellschaft Mbh sold 12,502 shares as 3M Co (MMM)’s stock declined 6.86%. The Meag Munich Ergo Kapitalanlagegesellschaft Mbh holds 1,500 shares with $313,000 value, down from 14,002 last quarter. 3M Co now has $120.92 billion valuation. The stock increased 1.52% or $3.15 during the last trading session, reaching $209.72. About 2.97M shares traded or 21.49% up from the average. 3M Company (NYSE:MMM) has declined 17.47% since February 14, 2018 and is downtrending. It has underperformed by 17.47% the S&P500. Some Historical MMM News: 30/04/2018 – 3M GETS FDA 510 K CLEARANCE FOR ATTEST SUPER RAPID INDICATOR; 15/05/2018 – Amphenol Corporation vs 3M Innovative Properties Company | Terminated-Dismissed | 05/15/2018; 25/05/2018 – Hartford Value HLS Adds US Foods Holding, Exits 3M Co; 08/05/2018 – 3M CO SAYS EXPECTS FY 2018 GROSS SHARE REPURCHASES WILL BE IN THE RANGE OF $3.0 BLN TO $5.0 BLN – SEC FILING; 09/05/2018 – 3M NAMES MOJDEH POUL EVP, SAFETY-GRAPHICS GROUP; 13/04/2018 – Canada 3M CDOR Yield at 1.93% by End-3Q vs 1.90% Prior (Survey); 24/04/2018 – 3M sinks 8%, eyes biggest drop since 2007; 24/04/2018 – PAVILLON: 3M UNPAID LEAVE FOR ZHENG FENGWEN, EXEC DIRECTOR, CEO; 30/05/2018 – 3M Announces Upcoming Investor Event; 18/04/2018 – S. Korea 3M Koribor Yield at 1.65% by End-2Q18 (Survey)

Epizyme Inc (EPZM) investors sentiment decreased to 1.28 in Q3 2018. It’s down -0.12, from 1.4 in 2018Q2. The ratio has dropped, as 46 investment managers started new or increased holdings, while 36 reduced and sold stock positions in Epizyme Inc. The investment managers in our database now hold: 56.53 million shares, down from 57.28 million shares in 2018Q2. Also, the number of investment managers holding Epizyme Inc in top ten holdings decreased from 2 to 1 for a decrease of 1. Sold All: 12 Reduced: 24 Increased: 30 New Position: 16.

Foresite Capital Management Ii Llc holds 5.62% of its portfolio in Epizyme, Inc. for 1.43 million shares. Nea Management Company Llc owns 6.46 million shares or 2.96% of their US portfolio. Moreover, Redmile Group Llc has 0.73% invested in the company for 2.25 million shares. The Massachusetts-based Opaleye Management Inc. has invested 0.54% in the stock. University Of Notre Dame Du Lac, a Indiana-based fund reported 272,476 shares.

The stock decreased 0.24% or $0.03 during the last trading session, reaching $12.6. About 620,404 shares traded. Epizyme, Inc. (EPZM) has declined 48.23% since February 14, 2018 and is downtrending. It has underperformed by 48.23% the S&P500. Some Historical EPZM News: 08/05/2018 – Epizyme 1Q Loss/Shr 49c; 13/03/2018 – EPIZYME 4Q LOSS/SHR 52C, EST. LOSS/SHR 57C; 13/03/2018 – Epizyme Expects Existing Cash, Equivalents and Securities Sufficient to Fund Planned Ops 3Q 2019; 23/04/2018 – EPIZYME INC EPZM.O – PARTIAL CLINICAL HOLD WAS INITIATED FOLLOWING A SAFETY REPORT, SUBMITTED BY EPIZYME TO FDA AND OTHER REGULATORY AUTHORITIES; 15/03/2018 – Epizyme Group Dinner Scheduled By Wedbush for Mar. 22; 05/04/2018 – EPIZYME, FILES MIXED SECURITIES SHELF; 08/05/2018 – EPIZYME 1Q LOSS/SHR 49C, EST. LOSS/SHR 54C; 12/03/2018 – Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors; 09/04/2018 – Epizyme: Study Demonstrated Favorable Safety Findings and Anti-Tumor Activity; 09/04/2018 – EPIZYME TAZEMETOSTAT PHASE 1 HAD FAVORABLE SAFETY FINDINGS

Analysts await Epizyme, Inc. (NASDAQ:EPZM) to report earnings on March, 12. They expect $-0.50 EPS, up 3.85% or $0.02 from last year’s $-0.52 per share. After $-0.54 actual EPS reported by Epizyme, Inc. for the previous quarter, Wall Street now forecasts -7.41% EPS growth.

More notable recent Epizyme, Inc. (NASDAQ:EPZM) news were published by: Seekingalpha.com which released: “Epizyme: Interesting, But Not For Us – Seeking Alpha” on February 04, 2019, also Nasdaq.com with their article: “What’s Behind the Biotech ETF Rally to Start 2019? – Nasdaq” published on January 24, 2019, Nasdaq.com published: “Why Is Epizyme (EPZM) Down 11.9% Since Last Earnings Report? – Nasdaq” on December 02, 2018. More interesting news about Epizyme, Inc. (NASDAQ:EPZM) were released by: Nasdaq.com and their article: “Epizyme (EPZM) Reports Narrower-than-Expected Q2 Loss – Nasdaq” published on August 02, 2018 as well as Seekingalpha.com‘s news article titled: “Epizyme working to lift partial clinical hold on tazemetostat – Seeking Alpha” with publication date: September 05, 2018.

Since January 1, 0001, it had 1 buying transaction, and 0 selling transactions for $3.75 million activity.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $997.52 million. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.

More notable recent 3M Company (NYSE:MMM) news were published by: Seekingalpha.com which released: “3M Q4 2018 Earnings Preview – Seeking Alpha” on January 28, 2019, also Seekingalpha.com with their article: “The Durability Of Innovation At 3M – Seeking Alpha” published on January 16, 2019, Seekingalpha.com published: “3M Company: 2019 To Be A Likely Dissappointment – Seeking Alpha” on January 20, 2019. More interesting news about 3M Company (NYSE:MMM) were released by: Seekingalpha.com and their article: “Reputation Alone Won’t Do It For 3M – Seeking Alpha” published on January 31, 2019 as well as 247Wallst.com‘s news article titled: “Earnings Preview: How 3M Could Rock the Dow – 24/7 Wall St.” with publication date: January 28, 2019.

Since September 10, 2018, it had 1 insider purchase, and 11 selling transactions for $17.53 million activity. Vrohidis Ippocratis sold $1.63 million worth of stock. On Friday, February 8 Keel Paul A sold $1.87M worth of 3M Company (NYSE:MMM) or 9,410 shares. $624,295 worth of 3M Company (NYSE:MMM) was sold by Bushman Julie L. THULIN INGE G also sold $2.66 million worth of 3M Company (NYSE:MMM) shares. Shares for $1.19 million were sold by Lindekugel Jon T. Vale Michael G. sold $1.77 million worth of stock or 8,906 shares. $3.22M worth of 3M Company (NYSE:MMM) was sold by Bauman James L on Monday, February 11.

Among 7 analysts covering 3M (NYSE:MMM), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. 3M had 12 analyst reports since August 21, 2018 according to SRatingsIntel. The firm has “Neutral” rating by UBS given on Thursday, August 30. Argus Research maintained it with “Buy” rating and $225 target in Wednesday, October 24 report. As per Friday, November 16, the company rating was maintained by Deutsche Bank. The stock of 3M Company (NYSE:MMM) earned “Neutral” rating by UBS on Wednesday, October 24. The firm has “Outperform” rating given on Wednesday, October 24 by Credit Suisse. Barclays Capital maintained 3M Company (NYSE:MMM) rating on Wednesday, October 24. Barclays Capital has “Underweight” rating and $195 target. As per Wednesday, October 24, the company rating was maintained by Citigroup. On Monday, November 19 the stock rating was maintained by Barclays Capital with “Underweight”. The firm has “Underweight” rating by Barclays Capital given on Thursday, January 3. As per Friday, September 28, the company rating was maintained by Deutsche Bank.

Investors sentiment increased to 1.03 in 2018 Q3. Its up 0.06, from 0.97 in 2018Q2. It increased, as 47 investors sold MMM shares while 535 reduced holdings. 117 funds opened positions while 480 raised stakes. 371.40 million shares or 0.76% less from 374.25 million shares in 2018Q2 were reported. New Mexico Educational Retirement Board invested 0.42% in 3M Company (NYSE:MMM). Moreover, Hartwell J M Ltd Partnership has 0.05% invested in 3M Company (NYSE:MMM). Guggenheim Cap Ltd Liability accumulated 187,323 shares or 0.26% of the stock. Old Second Bancshares Of Aurora has invested 0.14% in 3M Company (NYSE:MMM). Cwm Llc holds 0.02% in 3M Company (NYSE:MMM) or 4,144 shares. 18,796 were reported by Beck Mack & Oliver Limited Liability Com. Carlton Hofferkamp Jenks Wealth Mgmt Ltd stated it has 0.87% of its portfolio in 3M Company (NYSE:MMM). Trust Of Virginia Va reported 13,268 shares. Banque Pictet And Cie has invested 2.83% in 3M Company (NYSE:MMM). Argi Inv Service Lc invested in 3,263 shares or 0.04% of the stock. Exchange Capital Mngmt Inc reported 5,152 shares. Virginia-based Heritage Wealth Advisors has invested 0.09% in 3M Company (NYSE:MMM). Eqis Cap Mngmt Inc owns 0.12% invested in 3M Company (NYSE:MMM) for 9,272 shares. State Of Alaska Department Of Revenue stated it has 160,878 shares or 0.57% of all its holdings. Archford Strategies Ltd Liability Co holds 0.17% of its portfolio in 3M Company (NYSE:MMM) for 2,206 shares.

Epizyme, Inc. (NASDAQ:EPZM) Institutional Positions Chart